Analyst Price Targets — ALEC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 4, 2026 12:16 pm | — | Morgan Stanley | $2.00 | $2.45 | TheFly | Alector price target raised to $2 from 90c at Morgan Stanley |
| October 22, 2025 1:05 pm | — | H.C. Wainwright | $5.00 | $3.21 | TheFly | Alector price target lowered to $5 from $10 at H.C. Wainwright |
| October 22, 2025 8:38 am | — | Mizuho Securities | $1.50 | $3.21 | TheFly | Alector downgraded to Neutral from Outperform at Mizuho |
| November 19, 2024 9:07 pm | Corinne Jenkins | Goldman Sachs | $4.00 | $5.08 | StreetInsider | Goldman Sachs Reiterates Sell Rating on Alector Inc. (ALEC) |
Latest News for ALEC
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.41 per share a year ago.
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies)
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALEC.
U.S. House Trading
No House trades found for ALEC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.